HRD status variation in consecutive tumour biopsies in a pan-cancer cohort: a descriptive single-center study including patients from the Phase 1 Unit, Copenhagen University Hospital, Rigshospitalet
When testing for HRD, sensitivity to normal tissue in tumour samples has proven more consequential than previously expected. Based on our findings, HRD status rarely changes over time, and changes in HRD scores may not reflect a genuine biological shift. Therefore, patients considered for clinical trials based on historic HRD status may not need confirmatory biopsies after intervening treatment, thereby sparing patients from unnecessary procedures.
Authors
- Daniela Alosi
- Martin Højgaard (ORCID: https://orcid.org/0000-0003-1850-535X)
- Rosa Damkjær Britton
- Luca Robinson (ORCID: https://orcid.org/0000-0003-2561-2858)
- Kristoffer Staal Rohrberg (ORCID: https://orcid.org/0000-0002-5448-9003)
- Maria Rossing (ORCID: https://orcid.org/0000-0003-4325-3027)
- Maj K. Kjeldsen (ORCID: https://orcid.org/0000-0001-5787-5412)
- Ida Kappel Buhl (ORCID: https://orcid.org/0000-0003-3299-1358)
- Iben Spanggaard (ORCID: https://orcid.org/0000-0001-5925-2630)
- Ulrik Lassen (ORCID: https://orcid.org/0000-0002-3865-4574)
Institutions
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Cancer Genetics
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1016/j.cancergen.2025.05.004
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Arvid Nilssons Fond
- Region Hovedstaden